INO's latest try at bringing a treatment to market is INO-3107, for which it expects to submit a BLA in the second half of 2024. Potential market size if the BLA is successful is $770 million ...
DON is the most common entity to affect the afferent visual pathways in MS, while saccadic abnormalities, INO, smooth pursuit abnormalities and abnormalities of the VOR are among the more common ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...